Buy BSX by Oct 27, 2026.

Was watching this one closely this morning as the stock had dropped significantly recently and was trading at a multi year low. BSX Beat Q2 expectations (Rev $5.44B vs $5.39B, EPS $0.86 vs $0.83). Personally, I've been getting more into what I view as undervalued MedTech (recently posted on ISRG which hit lows around 330) and this feels like another dominant company in medical devices that should rebound nicely, even if competition gains ground in specific segments, I like the …